Skadden advised Innovent Biologics, Inc., a leading biopharmaceutical company, on its HK$4.3 billion (approximately US$550 million) placing of new shares. The transaction was completed on July 4, 2025.
The Skadden team was led by China practice co-head Paloma Wang, supported by counsel Martina To and associate Angela Cheng.
